Immunomedics

Blockbusters in waiting: drug launches to watch in 2020
Pharmaforum
Mon, 02/17/20 - 11:33 pm
drug launches
Biohaven
rimegepant
Novartis
ofatumumab
Celgene
ozanimod
Akebia Therapeutics
vadadustat
Biomarin
valrox
Gilead Sciences
filgotinib
Novo Nordisk
oral semaglutide
inclisiran
Immunomedics
sacituzumab govitecan
AstraZeneca
Enhertu
Bristol-Myers Squibb
liso-cel
These 3 Biotech Stocks Could Be Top Stocks in 2020
Motley Fool
Sun, 01/12/20 - 11:19 pm
Biomarin
Iovance
Immunomedics
Corporate and regulatory developments over the Christmas period
EP Vantage
Thu, 01/2/20 - 11:39 pm
Astellas
M&A
Qiagen
AstraZeneca
Bausch Health
BeiGene
Celyad
Immunomedics
Merck
Merck KGaA
Ono Pharmaceutical
Pfizer
Pharming
Xyphos Biosciences
Troubled Immunomedics tries again at FDA after rejection
Fierce Biotech
Thu, 12/5/19 - 10:07 am
Immunomedics
IMMU-132
sacituzumab govitecan
FDA
metastatic triple-negative breast cancer
After FDA rejection, Immunomedics tries again with breast cancer drug
Biopharma Dive
Tue, 12/3/19 - 10:23 pm
Immunomedics
breast cancer
sacituzumab govitecan
metastatic triple-negative breast cancer
FDA
2 Biotechs With Approaching Drug Approvals
Motley Fool
Sun, 10/13/19 - 11:30 pm
drug approvals
drug launches
FDA
voxelotor
Global Blood Therapeutics
Immunomedics
sacituzumab govitecan
The Week Ahead In Biotech: Spotlight On ESMO Conference
Yahoo/Benzinga
Sun, 09/22/19 - 11:10 pm
JNJ
daratumumab
Urogen
Rhythm Pharmaceuticals
Anavex
Aravive Biologics
TrovaGene
Incyte
AstraZeneca
Roche
Amgen
Aslan
G1 Therapeutics
GSK
Calithera Biosciences
Seattle Genetics
Immunomedics
Checkpoint Therapeutics
Aileron Therapeutics
Genocea Biosciences
AbbVie
Zymeworks
These 6 biotech stocks are promising takeover targets
Marketwatch
Thu, 05/2/19 - 11:33 am
M&A
Sarepta Therapeutics
Amarin
Intercept Pharmaceuticals
Immunomedics
Alder Biopharmaceuticals
Biogen
With Immunomedics ADC deal, Everest bolsters cancer pipeline
BioCentury
Mon, 04/29/19 - 08:50 pm
Immunomedics
sacituzumab govitecan
Everest Medicines
Asia
Immunomedics CEO Michael Pehl hits the exit on the heels of a CRL and accusations of a data integrity breach
Endpoints
Mon, 02/25/19 - 11:53 pm
Immunomedics
Michael Pehl
FDA uncovers data manipulation at Immunomedics plant making cancer drug
Fierce Pharma
Thu, 02/14/19 - 10:02 am
FDS
Immunomedics
sacituzumab govitecan
drug manufacturing
Immunomedics, still searching for first approval, discloses forthcoming FDA re-inspection
Biopharma Dive
Sat, 02/9/19 - 12:14 am
Immunomedics
FDA
sacituzumab govitecan
FDA rejects Immunomedics breast cancer drug, extending long regulatory drought
Stat
Fri, 01/18/19 - 12:12 am
Immunomedics
FDA
breast cancer
sacituzumab govitecan
FDA Grants Priority Review and accepts BLA for Sacituzumab Govitecan for the Treatment of Metastatic Triple-negative Breast Cancer
CP Wire
Wed, 07/18/18 - 09:29 am
Immunomedics
FDA
sacituzumab govitecan
triple negative breast cancer
Why Data at ASCO 2018 Sent Immunomedics Shares Soaring Today
Motley Fool
Mon, 06/4/18 - 10:09 pm
Immunomedics
ASCO 2018
sacituzumab govitecan
breast cancer
After months of searching, Immunomedics lines up Celgene vet Pehl as its new CEO
Fierce Biotech
Sat, 11/11/17 - 11:12 am
Immunomedics
Celgene
Pharma CEOs
Michael Pehl
Will Seattle Genetics' Deal With Immunomedics Get Scuttled?
Motley Fool
Mon, 02/13/17 - 10:02 am
Seattle Genetics
Immunomedics
IMMU-132
Immunomedics, Seattle Genetics Lead Biotech Movers on Deal News
TheStreet.com
Fri, 02/10/17 - 09:52 am
Immunomedics
Seattle Genetics
M&A
solid tumors
Adcetris
7 Biopharma Companies That Destroyed Shareholders Last Week
24/7 Wall St
Sun, 06/12/16 - 09:52 pm
ProNai
Adamis Pharmaceuticals
Ocular Therapeutics
Mirati Therapeutics
Immunomedics
Valeant Pharmacueticals
Biogen
Immunomedics' ASCO Letdown
Motley Fool
Sat, 06/11/16 - 09:57 am
ASCO 2016
Immunomedics

Pages